The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrolment: Data from a systematic review and meta-analysis

Seminars in Arthritis and Rheumatism

Volumn 43, Issue 6, 2014, Pages 730-737

  Favalli, Ennio Giulio ^a   Pregnolato, Francesca ^b   Biggioggero, Martina ^a,c   Meroni, Pier Luigi ^a,c  

^a ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Biologics; Damage progression; Meta analysis; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; RITUXIMAB; TOCILIZUMAB; ANTIBODY CONJUGATE; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; BONE EROSION; COMPARATIVE EFFECTIVENESS; DISEASE COURSE; DRUG EFFICACY; ECHOGRAPHY; FOLLOW UP; HUMAN; META ANALYSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT OUTCOME; ARTHRITIS, RHEUMATOID; DRUG COMBINATION; RADIOGRAPHY; STATISTICAL BIAS; TIME;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIAS (EPIDEMIOLOGY); BIOLOGICAL PRODUCTS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN G; METHOTREXATE; RECEPTORS, TUMOR NECROSIS FACTOR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84902545997     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2013.11.006     Document Type: Article

References (47)

1. Sokka T., Abelson B., Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008, 26(5 SUPPL. 51):S35-S61.
2. Welsing P.M.J., Landew R.B.M., van Riel P.L.C.M., Boers M., Van Gestel A.M., van der Linden S., et al. The relationship between disease activity and radiologic progression in patients with rheumatoid arthritis: a longitudinal analysis. Arthritis Rheum 2004, 50:2082-2093.
3. Goekoop-Ruiterman Y.P.M., de Vries-Bouwstra J.K., Allaart C.F., van Zeben D., Kerstens PJSM, Hazes JMW, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005, 52:3381-3390.
4. Moher D., Liberati A., Tetzlaff J., Altman D.G. PRISMA group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009, 151:264-269.
5. Sharp J.T., Lidsky M.D., Collins L.C., Moreland L.W. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum 1971, 14:706-720.
6. van der Heijde D.M. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000, 27:261-263.
7. Genant H.K. Methods of assessing radiographic change in rheumatoid arthritis. Am J Med 1983, 75:35-47.
8. Lassere M. Pooled metaanalysis of radiographic progression: comparison of Sharp and Larsen methods. J Rheumatol 2000, 27:269-275.
9. Elbourne D.R., Altman D.G., Higgins J.P.T., Curtin F., Worthington H.V., Vail A. Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 2002, 31:140-149.
10. van Houwelingen H.C., Arends L.R., Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 2002, 21:589-624.
11. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
12. Lewis S., Clarke M. Forest plots: trying to see the wood and the trees. Br Med J 2001, 322:1479-1480.
13. Keystone E.C., van der Heijde D.M., Mason D., Landewé R., van Vollenhoven R.F., Combe B., et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008, 58:3319-3329.
14. Emery P., Breedveld F.C., Hall S., Durez P., Chang D.J., Robertson D., et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008, 372:375-382.
15. Genovese M.C., Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002, 46:1443-1450.
16. St Clair E.W., van der Heijde D.M., Smolen J.S., Maini R.N., Bathon J.M., Emery P., et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004, 50:3432-3443.
17. Klareskog L., van der Heijde D.M., de Jager J.P., Gough A., Kalden J.R., Malaise M., et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004, 363:675-681.
18. Keystone E.C., Kavanaugh A., Sharp J.T., Tannenbaum H., Hua Y., Teoh L.S., et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004, 50:1400-1411.
19. Breedveld F.C., Weisman M.H., Kavanaugh A., Cohen S.B., Pavelka K., van Vollenhoven R.F., et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2005, 54:26-37.
20. Kremer J.M., Genant H.K., Moreland L.W., Russell A.S., Emery P., Abud-Mendoza C., et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006, 144:865-876.
21. Nishimoto N., Hashimoto J., Miyasaka N., Yamamoto K., Kawai S., Takeuchi T., et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007, 66:1162-1167.
22. Westhovens R., Robles M., Ximenes A.C., Nayiager S., Wollenhaupt J., Durez P., et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009, 68:1870-1877.
23. Emery P., Fleischmann R.M., van der Heijde D.M., Keystone E.C., Genovese M.C., Conaghan P.G., et al. The effects of golimumab on radiographic progression in rheumatoid arthritis: results of randomized controlled studies of golimumab before methotrexate therapy and golimumab after methotrexate therapy. Arthritis Rheum 2011, 63:1200-1210.
24. Lipsky P.E., van der Heijde D.M., Clair E.W.S., Furst D.E., Breedveld F.C., Kalden J.R., et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000, 343:1594-1602.
25. Keystone E.C., Emery P., Peterfy C.G., Tak P.P., Cohen S., Genovese M.C., et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2009, 68:216-221.
26. Tak P.P., Rigby W.F., Rubbert-Roth A., Peterfy C.G., van Vollenhoven R.F., Stohl W., et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 2011, 70:39-46.
27. Kremer J.M., Russell A.S., Emery P., Abud-Mendoza C., Szechinski J., Westhovens R., et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis 2011, 70:1826-1830.
28. van der Heijde D.M., van Leeuwen M.A., van Riel P.L., Koster A.M., van't Hof M.A., van Rijswijk M.H., et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. Arthritis Rheum 1992, 35:26-34.
29. Plant M.J., Saklatvala J., Borg A.A., Jones P.W., Dawes P.T. Measurement and prediction of radiological progression in early rheumatoid arthritis. J Rheumatol 1994, 21:1808-1813.
30. Peterfy C.G., Wu C., Szechinski J., DiCarlo J.C., Lu Y., Genovese M.C., et al. Comparison of the Genant-modified Sharp and van der Heijde-modified Sharp scoring methods for radiographic assessment in rheumatoid arthritis. Int J Clin Rheumatol 2011, 6:15-24.
31. Sharp J.T., Wolfe F., Lassere M., Boers M., van der Heijde D.M., Larsen A., et al. Variability of precision in scoring radiographic abnormalities in rheumatoid arthritis by experienced readers. J Rheumatol 2004, 31:1062-1072.
32. Lassere M.N., van der Heijde D.M., Johnson K., Bruynesteyn K., Molenaar E., Boonen A., et al. Robustness and generalisability of smallest detectable difference in radiological progression. J Rheumatol 2001, 28:911-913.
33. Sismondo S. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials 2008, 29:109-113.
34. Graudal N., Jürgens G. Similar effects of disease-modifying antirheumatic drugs, glucocorticoids, and biologic agents on radiographic progression in rheumatoid arthritis: meta-analysis of 70 randomized placebo-controlled or drug-controlled studies, including 112 comparisons. Arthritis Rheum 2010, 62:2852-2863.
35. Favalli E.G., Pregnolato F., Biggioggero M., Meroni P.L. The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials. Ther Adv Musculoskelet Dis 2012, 4:213-223.
36. Messori A., Del Santo F., Maratea D., Fadda V., Trippoli S. Interpreting randomised trials evaluating newer agents or interferon in multiple sclerosis. Eur J Clin Pharmacol 2012, 68:1225-1226.
37. Vasques F., Messori A., Lucenteforte E., Biancari F. Immediate and late outcome of patients aged 80 years and older undergoing isolated aortic valve replacement: a systematic review and meta-analysis of 48 studies. Am Heart J 2012, 163:477-485.
38. Courvoisier N., Dougados M., Cantagrel A., Goupille P., Meyer O., Sibilia J., et al. Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study. Arthritis Res Ther 2008, 10:R106.
39. Singh J.A., Christensen R., Wells G.A., Suarez-Almazor M.E., Buchbinder R., Lopez-Olivo M.A., et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009, CD007848.
40. Hulsmans H.M., Jacobs J.W., van der Heijde D.M., van Albada-Kuipers G.A., Schenk Y., Bijlsma J.W.J. The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum 2000, 43:1927-1940.
41. Wolfe F., Sharp J.T. Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis Rheum 1998, 41:1571-1582.
42. Plant M.J., Jones P.W., Saklatvala J., Ollier W.E., Dawes P.T. Patterns of radiological progression in early rheumatoid arthritis: results of an 8 year prospective study. J Rheumatol 1998, 25:417-426.
43. Mcinnes I.B., Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011, 365:2205-2219.
44. Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford) 2012, 51(SUPPL. 5):v3-v11.
45. van der Heijde D.M. Erosions versus joint space narrowing in rheumatoid arthritis: what do we know?. Ann Rheum Dis 2011, 70(SUPPL. 1):i116-i118.
46. Rahman M.U., Buchanan J., Doyle M.K., Hsia E.C., Gathany T., Parasuraman S., et al. Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. Ann Rheum Dis 2011, 70:1631-1640.
47. Strand V., Sokolove J. Randomized controlled trial design in rheumatoid arthritis: the past decade. Arthritis Res Ther 2009, 11:205.